Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in Moderate-to-severe Non-pustular Palmoplantar Psoriasis
NCT07752108Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Nov 2026
- Primary completion
- May 2027
01
Overview
A Phase 3 trial of zasocitinib in palmoplantar psoriasis, sponsored by Takeda. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
zasocitinib
03
Conditions
palmoplantar psoriasis
Beyond the preview
Go deeper on NCT07752108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752108.